Effect of retransfusion after hemorrhagic hypotension on intrarenal distribution of blood flow in dogs.
Hemorrhagic hypotension in anesthetized dogs produces a marked decrease of the cortical blood flow, whereas the medullary blood flow is well preserved. These animals were maintained at blood pressures of 50 mm Hg during a 3 hr period after which their blood pressures were restored by the reinfusion of blood or dextran, or both. In the first group of animals, the reinfusion of blood reestablished the blood pressure to control values, but the cortical blood flow was still nonuniformly decreased whereas the medullary blood flow appeared to be increased. In the second group of animals, phenoxybenzamine failed to protect the kidney completely since after blood reinfusion, the same anomalies described for the preceding group were found in 7 out of 10 dogs. The animals of the third group were reinfused with 50% of the shed blood and 10 ml/kg of a 10 g/100 ml solution of low molecular weight dextran. The modifications of the intrarenal distribution of the blood flow were less marked in this group although the blood flow rate of the inner cortex and the outer medulla was always elevated under these conditions. The reinfusion of low molecular weight dextran alone (20 ml/kg of a 10 g/100 ml solution) restored the blood pressure to levels slightly lower than those observed under control conditions but reestablished a normal pattern of intrarenal blood flow. The reinfusion of high molecular weight dextran was inefficient in correcting completely the anomalies of the renal blood flow. Mechanisms such as the increased sympathetic tone, the liberation of angiotensin, and the intravascular cellular aggregation could possibly account for the persisting anomalies of the renal circulation after reinfusion and are discussed.
D000818:Animals; D001345:Autoradiography; D001783:Blood Flow Velocity; D001794:Blood Pressure; D001804:Blood Transfusion, Autologous; D003911:Dextrans / Q000494:pharmacology*; D004285:Dogs; D006470:Hemorrhage / Q000628:therapy*; D006977:Hypertension, Renal / Q000628:therapy*; D007668:Kidney / Q000098:blood supply* / Q000187:drug effects; D007726:Krypton; D010643:Phenoxybenzamine / Q000494:pharmacology; D010952:Plasma Substitutes / Q000494:pharmacology*; D011868:Radioisotopes; D013997:Time Factors
D003911:Dextrans; D010952:Plasma Substitutes; D011868:Radioisotopes; D010643:Phenoxybenzamine; D007726:Krypton